Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy
Gaëlle Montes(University Dermatology), S. Prey(Université de Bordeaux), Guilhem Solé(Université de Bordeaux), Céline Eldani(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), S. Amico(University Dermatology), E. Gérard(Université de Bordeaux), Clémence Guerin(Roche (France)), Louis Carla(Neurology, Inc), Fanny Duval, P. Celérier(Roche (France)), Cécile Herran(Centre Hospitalier Universitaire de Bordeaux), Florian Poullenot(Bordeaux Population Health)
Cited by 8
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k